Drug Trial Radar · NCT06084598
A Study to Evaluate the Safety, Tolerability and Drug Levels of BMS-986446 in Healthy Participants and Healthy Participants of Japanese Ethnicity
Last checked: Nov 19, 2026Latest source record: Mar 15, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
24
Actual
Start
Oct 12, 2023
Primary completion
Mar 8, 2024
Study completion Mar 8, 2024
Sponsor
- Lead sponsor
- Bristol-Myers SquibbBristol Myers Squibb (BMY)
- Sponsor type
- Industry
- First posted
- Oct 16, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the safety, tolerability and drug levels of BMS-986446 in healthy participants including healthy participants of Japanese ethnicity.
Conditions
- Healthy Participants
Interventions
BMS-986446Drug
Specified dose on specified days
PlaceboOther
Specified dose on specified days
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of adverse events (AEs)Time frame: Up to Day 85
- Number of participants with vital sign abnormalitiesTime frame: Up to Day 85
- Number of participants with electrocardiogram (ECG) abnormalitiesTime frame: Up to Day 85
- Number of participants with physical examination abnormalitiesTime frame: Up to Day 85
- Number of participants with body weight abnormalitiesTime frame: Up to Day 85
- Number of participants with clinical laboratory abnormalitiesTime frame: Up to Day 85
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Local Institution - 0001
Cypress, California
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.